Effect of Qihuang Jianpi Zishen Granules for Treat-to-target on Renal Podocyte Injury Markers in Patients with Systemic Lupus Erythematosus
10.13422/j.cnki.syfjx.20260795
- VernacularTitle:芪黄健脾滋肾颗粒对系统性红斑狼疮患者达标治疗及肾足细胞损伤标志物的影响
- Author:
Junjie CHEN
1
;
Chuanbing HUANG
2
;
Tianshu WANG
3
;
Ming LI
2
;
Lili CHENG
1
;
Zhongfu TANG
1
Author Information
1. Anhui University of Chinese Medicine，Hefei 230031，China
2. Institute of Xin'an Medicine and Modernization of Traditional Chinese Medicine，The First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China
3. The First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China
- Publication Type:Journal Article
- Keywords:
Qihuang Jianpi Zishen granules;
systemic lupus erythematosus;
podocytes;
podocyte injury markers;
apoptosis
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(23):169-177
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical efficacy of Qihuang Jianpi Zishen granules in the treatment of systemic lupus erythematosus （SLE），observe their effects on renal podocyte injury，and decipher related mechanisms. MethodsSixty-two SLE patients with renal damage who met the inclusion criteria and treated in the First Affiliated Hospital of Anhui University of Chinese Medicine between November 2022 and July 2024 were selected. They were randomly allocated into a control group and an observation group （31 patients in each group）. The control group was treated with oral hydroxychloroquine sulfate，prednisone acetate，and mycophenolate mofetil. The observation group received Qihuang Jianpi Zishen granules orally in addition to the regimen in the control group. After 12 weeks of continuous treatment，the SLE Responder Index-4 （SRI-4） response rate was evaluated for both groups. Comparisons were made between the two groups before and after treatment regarding disease activity scores，traditional Chinese medicine （TCM） symptom scores，kidney-related indicators ［serum creatinine （SCr），cystatin C （Cys C），24-hour urine protein quantitation （24 h Pro），urine protein/creatinine ratio （UPCR），and urine albumin/creatinine ratio （UACR）］，immune and inflammatory markers ［anti-double-stranded DNA antibody，interferon-γ （IFN-γ），and monocyte chemoattractant protein-1 （MCP-1）］，urinary podocyte injury markers （Nephrin，Podocin，and WT-1），and mRNA levels of apoptosis-related factors （Bax，Bcl-2，and Caspase-3） in peripheral blood mononuclear cells. Adverse reactions were recorded. ResultsAfter 12 weeks of treatment，the SRI-4 response rate in the observation group was 48.38%（15/31），which was higher than that in the control group 36.66%（11/30）. Within-group comparisons showed that after treatment，both groups exhibited decreases in TCM symptom scores，kidney-related indicators （UACR，UPCR，24 h Pro，SCr，and CysC），inflammatory markers （IFN-γ and MCP-1），podocyte injury markers （Nephrin，Podocin，and WT-1），and the mRNA levels of Bax and Caspase-3 （P<0.05，P<0.01） and an increase in the mRNA level of Bcl-2 （P<0.01）. After treatment，the observation group showed lower disease activity score，TCM symptom scores，levels of UACR，UPCR，24 h Pro，SCr，IFN-γ，MCP-1，and podocyte injury markers （Nephrin，Podocin，WT-1），and mRNA level of Bax （P<0.05，P<0.01） and higher mRNA level of Bcl-2 （P<0.05） than the control group. No serious adverse reactions occurred during the treatment period. ConclusionQihuang Jianpi Zishen granules can effectively reduce the disease activity，TCM symptoms，proteinuria，podocyte injury，and renal damage in patients with SLE by regulating the immune-inflammatory state，mitigating podocyte injury，and inhibiting cell apoptosis.
